Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis

Vanessa Roldán; Francisco Marín

doi:10.1055/s-0038-1641737

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2018; 118(05): 806-807
DOI: 10.1055/s-0038-1641737

Invited Editorial Focus

Schattauer GmbH Stuttgart

Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis

Vanessa Roldán

¹Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, IMIB-Arrixaca, Universidad de Murcia, Murcia, Spain

,

Francisco Marín

²Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, CIBER-CV, Universidad de Murcia, Murcia, Spain

› Author Affiliations

Abstract

Full Text

References

References
1 Lip GYH, Collet JP, de Caterina R. , et al. Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: executive summary of a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). Thromb Haemost 2017; 117 (12) 2215-2236
2 De Caterina R, Husted S, Wallentin L. , et al. Vitamin K antagonists in heart disease: current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis--Task Force on Anticoagulants in Heart Disease. Thromb Haemost 2013; 110 (06) 1087-1107
3 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2, Suppl): e44S-e88S
4 Esteve-Pastor MA, Rivera-Caravaca JM, Roldán-Rabadán I. , et al; FANTASIIA Study Investigators. Relation of renal dysfunction to quality of anticoagulation control in patients with atrial fibrillation: the FANTASIIA Registry. Thromb Haemost 2018; 118 (02) 279-287
5 Pérez-Andreu V, Roldán V, González-Conejero R, Hernández-Romero D, Vicente V, Marín F. Implications of pharmacogenetics for oral anticoagulants metabolism. Curr Drug Metab 2009; 10 (06) 632-642
6 Keeling D, Baglin T, Tait C. , et al; British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol 2011; 154 (03) 311-324
7 Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69 (03) 236-239
8 Gupta S, Belley-Cote EP, Sarkaria A. , et al. INR targets for left-sided mechanical valve replacement. A systematic review and meta-analysis. Thromb Haemost 2018; 118 (05)
9 Pourgholi L, Goodarzynejad H, Mandegary A. , et al. Gene polymorphisms and the risk of warfarin-induced bleeding complications at therapeutic international normalized ratio (INR). Toxicol Appl Pharmacol 2016; 309: 37-43
10 Ibrahim S, Jespersen J, Poller L. ; European Action on Anticoagulation. The clinical evaluation of international normalized ratio variability and control in conventional oral anticoagulant administration by use of the variance growth rate. J Thromb Haemost 2013; 11 (08) 1540-1546
11 Rosendaal FR, Cannegieter SC. Control of anticoagulation with VKAs: overestimation of median TTR when assessed by linear extrapolation: a comment. Thromb Haemost 2017; 117 (04) 819
12 van den Besselaar AMHP, Biedermann JS, van der Meer FJM, Adriaansen HJ, Leebeek FWG, Kruip MJHA. Control of anticoagulation with vitamin K antagonists: overestimation of median time in therapeutic range when assessed by linear interpolation. Thromb Haemost 2016; 116 (04) 679-686
13 Kirchhof P, Benussi S, Kotecha D. , et al; ESC Scientific Document Group. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37 (38) 2893-2962
14 Gallagher AM, Setakis E, Plumb JM, Clemens A, van Staa TP. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. Thromb Haemost 2011; 106 (05) 968-977
15 Van Den Ham HA, Klungel OH, Leufkens HG, Van Staa TP. The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation. J Thromb Haemost 2013; 11 (01) 107-115
16 Vestergaard AS, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: a systematic review and meta-regression analysis. PLoS One 2017; 12 (11) e0188482
17 Grzymala-Lubanski B, Svensson PJ, Renlund H, Jeppsson A, Själander A. Warfarin treatment quality and prognosis in patients with mechanical heart valve prosthesis. Heart 2017; 103 (03) 198-203
18 Labaf A, Svensson PJ, Renlund H, Jeppsson A, Själander A. Incidence and risk factors for thromboembolism and major bleeding in patients with mechanical valve prosthesis: a nationwide population-based study. Am Heart J 2016; 181: 1-9
19 Roldán V, Marín F. The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thromb Haemost 2015; 113 (04) 671-673